These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 20062093)

  • 1. Caspofungin first-line therapy for invasive aspergillosis in allogeneic hematopoietic stem cell transplant patients: an European Organisation for Research and Treatment of Cancer study.
    Herbrecht R; Maertens J; Baila L; Aoun M; Heinz W; Martino R; Schwartz S; Ullmann AJ; Meert L; Paesmans M; Marchetti O; Akan H; Ameye L; Shivaprakash M; Viscoli C
    Bone Marrow Transplant; 2010 Jul; 45(7):1227-33. PubMed ID: 20062093
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An EORTC Phase II study of caspofungin as first-line therapy of invasive aspergillosis in haematological patients.
    Viscoli C; Herbrecht R; Akan H; Baila L; Sonet A; Gallamini A; Giagounidis A; Marchetti O; Martino R; Meert L; Paesmans M; Ameye L; Shivaprakash M; Ullmann AJ; Maertens J;
    J Antimicrob Chemother; 2009 Dec; 64(6):1274-81. PubMed ID: 19841031
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Caspofungin for the treatment of invasive fungal disease in hematological patients (ProCAS Study).
    Jarque I; Tormo M; Bello JL; Rovira M; Batlle M; Julià A; Tabares S; Rivas C; Fernández-Sevilla A; García-Boyero R; Debén G; González-Campos J; Capote FJ; Sanz MA;
    Med Mycol; 2013 Feb; 51(2):150-4. PubMed ID: 22712457
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A prospective, multicenter study of caspofungin for the treatment of documented Candida or Aspergillus infections in pediatric patients.
    Zaoutis TE; Jafri HS; Huang LM; Locatelli F; Barzilai A; Ebell W; Steinbach WJ; Bradley J; Lieberman JM; Hsiao CC; Seibel N; Laws HJ; Gamba M; Petrecz M; Taylor AF; Strohmaier KM; Chow JW; Kartsonis NA; Ngai AL
    Pediatrics; 2009 Mar; 123(3):877-84. PubMed ID: 19255017
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multicenter, noncomparative study of caspofungin in combination with other antifungals as salvage therapy in adults with invasive aspergillosis.
    Maertens J; Glasmacher A; Herbrecht R; Thiebaut A; Cordonnier C; Segal BH; Killar J; Taylor A; Kartsonis N; Patterson TF; Aoun M; Caillot D; Sable C;
    Cancer; 2006 Dec; 107(12):2888-97. PubMed ID: 17103444
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Caspofungin as first-line therapy for the treatment of invasive aspergillosis after thoracic organ transplantation.
    Groetzner J; Kaczmarek I; Wittwer T; Strauch J; Meiser B; Wahlers T; Daebritz S; Reichart B
    J Heart Lung Transplant; 2008 Jan; 27(1):1-6. PubMed ID: 18187079
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Caspofungin as salvage monotherapy for invasive aspergillosis in patients with haematological malignancies or following allogeneic stem cell transplantation: efficacy and concomitant cyclosporin A.
    Morrissey CO; Slavin MA; O'Reilly MA; Daffy JR; Seymour JF; Schwarer AP; Szer J
    Mycoses; 2007; 50 Suppl 1():24-37. PubMed ID: 17394607
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Caspofungin use in daily clinical practice for treatment of invasive aspergillosis: results of a prospective observational registry.
    Maertens J; Egerer G; Shin WS; Reichert D; Stek M; Chandwani S; Shivaprakash M; Viscoli C;
    BMC Infect Dis; 2010 Jun; 10():182. PubMed ID: 20569436
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Caspofungin for post solid organ transplant invasive fungal disease: results of a retrospective observational study.
    Winkler M; Pratschke J; Schulz U; Zheng S; Zhang M; Li W; Lu M; Sgarabotto D; Sganga G; Kaskel P; Chandwani S; Ma L; Petrovic J; Shivaprakash M
    Transpl Infect Dis; 2010 Jun; 12(3):230-7. PubMed ID: 20070619
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Breakthrough invasive aspergillosis in allogeneic haematopoietic stem cell transplant recipients treated with caspofungin.
    Madureira A; Bergeron A; Lacroix C; Robin M; Rocha V; de Latour RP; Ferry C; Devergie A; Lapalu J; Gluckmana E; Socié G; Ghannoum M; Ribaud P
    Int J Antimicrob Agents; 2007 Dec; 30(6):551-4. PubMed ID: 18029149
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Micafungin alone or in combination with other systemic antifungal therapies in hematopoietic stem cell transplant recipients with invasive aspergillosis.
    Kontoyiannis DP; Ratanatharathorn V; Young JA; Raymond J; Laverdière M; Denning DW; Patterson TF; Facklam D; Kovanda L; Arnold L; Lau W; Buell D; Marr KA
    Transpl Infect Dis; 2009 Feb; 11(1):89-93. PubMed ID: 18983417
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of caspofungin in critically ill patients. ProCAS Study.
    León-Gil C; Ubeda-Iglesias A; Loza-Vázquez A; de la Torre MV; Raurich-Puigdevall JM; Alvarez-Sánchez B; Ortiz-Leyva C; Domínguez-Roldán JM; Socías-Crespi L; Garnacho-Montero J;
    Rev Esp Quimioter; 2012 Dec; 25(4):274-82. PubMed ID: 23303260
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of caspofungin against invasive Candida or invasive Aspergillus infections in neutropenic patients.
    Betts R; Glasmacher A; Maertens J; Maschmeyer G; Vazquez JA; Teppler H; Taylor A; Lupinacci R; Sable C; Kartsonis N
    Cancer; 2006 Jan; 106(2):466-73. PubMed ID: 16353208
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and efficacy of a caspofungin-based combination therapy for treatment of proven or probable aspergillosis in pediatric hematological patients.
    Cesaro S; Giacchino M; Locatelli F; Spiller M; Buldini B; Castellini C; Caselli D; Giraldi E; Tucci F; Tridello G; Rossi MR; Castagnola E
    BMC Infect Dis; 2007 Apr; 7():28. PubMed ID: 17442100
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies.
    Kontoyiannis DP; Hachem R; Lewis RE; Rivero GA; Torres HA; Thornby J; Champlin R; Kantarjian H; Bodey GP; Raad II
    Cancer; 2003 Jul; 98(2):292-9. PubMed ID: 12872348
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Salvage therapy with caspofungin for invasive aspergillosis: results from the caspofungin compassionate use study.
    Kartsonis NA; Saah AJ; Joy Lipka C; Taylor AF; Sable CA
    J Infect; 2005 Apr; 50(3):196-205. PubMed ID: 15780413
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of caspofungin as salvage therapy for invasive aspergillosis compared to standard therapy in a historical cohort.
    Hiemenz JW; Raad II; Maertens JA; Hachem RY; Saah AJ; Sable CA; Chodakewitz JA; Severino ME; Saddier P; Berman RS; Ryan DM; Dinubile MJ; Patterson TF; Denning DW; Walsh TJ
    Eur J Clin Microbiol Infect Dis; 2010 Nov; 29(11):1387-94. PubMed ID: 20703506
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical experience of the use of voriconazole, caspofungin or the combination in primary and salvage therapy of invasive aspergillosis in haematological malignancies.
    Raad II; Zakhem AE; Helou GE; Jiang Y; Kontoyiannis DP; Hachem R
    Int J Antimicrob Agents; 2015 Mar; 45(3):283-8. PubMed ID: 25455847
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Caspofungin plus posaconazole as salvage therapy of invasive fungal infections in immunocompromised patients.
    Lellek H; Waldenmaier D; Dahlke J; Ayuk FA; Wolschke C; Kröger N; Zander AR
    Mycoses; 2011 Jan; 54 Suppl 1():39-44. PubMed ID: 21126271
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Caspofungin as primary antifungal prophylaxis in stem cell transplant recipients.
    Chou LS; Lewis RE; Ippoliti C; Champlin RE; Kontoyiannis DP
    Pharmacotherapy; 2007 Dec; 27(12):1644-50. PubMed ID: 18041885
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.